<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277338</url>
  </required_header>
  <id_info>
    <org_study_id>Molecular imaging of HER2</org_study_id>
    <nct_id>NCT04277338</nct_id>
  </id_info>
  <brief_title>Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3</brief_title>
  <acronym>HE3-G3</acronym>
  <official_title>SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Technetium-99m-labelled Designed Ankyrin Repeat Proteins HE3-G3 (99mTc-HE3-G3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Bioorganic Chemistry, Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study should evaluate distribution of 99mTc-HE3-G3 in patients with primary HER2-positive&#xD;
      and HER2-negative breast cancer.&#xD;
&#xD;
      The primary objective are:&#xD;
&#xD;
        1. To assess distribution of 99mTc-HE3-G3 in normal tissues and in tumours over time;&#xD;
&#xD;
        2. To evaluate dosimetry of 99mTc-HE3-G3;&#xD;
&#xD;
        3. To obtain initial information concerning safety and tolerability of 99mTc-HE3-G3 after&#xD;
           single intravenous injection:&#xD;
&#xD;
      The secondary objective are:&#xD;
&#xD;
      1.To compare the tumour imaging data with the concerning HER2 expression obtained by&#xD;
      immunohistochemistry (IHC) or fluorescent in situ hybridisation (FISH) analysis of biopsy&#xD;
      samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall goal of the project: To determine HER2 expression level in primary breast cancer and&#xD;
      possibly in axillary lymph node metastases before neoadjuvant trastuzumab therapy.&#xD;
&#xD;
      Phase I. Distribution of 99mTc-HE3-G3 in patients with primary breast cancer. The study&#xD;
      should evaluate distribution of 99mTc-HE3-G3 in patients with primary HER2-positive and&#xD;
      HER2-negative breast cancer.&#xD;
&#xD;
      The primary objective are:&#xD;
&#xD;
        1. To assess distribution of 99mTc-HE3-G3 in normal tissues and in tumours over time;&#xD;
&#xD;
        2. To evaluate dosimetry of 99mTc-HE3-G3;&#xD;
&#xD;
        3. To obtain initial information concerning safety and tolerability of 99mTc-HE3-G3 after&#xD;
           single intravenous injection:&#xD;
&#xD;
      The secondary objective are:&#xD;
&#xD;
      1. To compare the tumour imaging data with the concerning HER2 expression obtained by&#xD;
      immunohistochemistry (IHC) or fluorescent in situ hybridisation (FISH) analysis of biopsy&#xD;
      samples:&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Open-label, exploratory, single centre study. The subjects will receive a single injection of&#xD;
      the labelled tracer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Actual">October 4, 2021</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gamma camera-based whole-body 99mTc-HE3-G3 uptake value (%)</measure>
    <time_frame>6 hours</time_frame>
    <description>Whole-body 99mTc-HE3-G3 uptake coinciding with normal organs and tissues will be assessed using gamma camera and calculated as percentage (%) of the injected dose of the radiopharmaceutical</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SPECT-based 99mTc-HE3-G3 uptake value in tumor lesions (counts)</measure>
    <time_frame>6 hours</time_frame>
    <description>99mTc-HE3-G3 uptake coinciding with tumor lesions will be assessed using single-photon emission computed tomography and measured in counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SPECT-based 99mTc-HE3-G3background uptake value (counts)</measure>
    <time_frame>6 hours</time_frame>
    <description>Focal uptake of 99mTc-HE3-G3 in the regions without pathological findings will be assessed with SPECT and measured in counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor-to-background ratio (SPECT)</measure>
    <time_frame>6 hours</time_frame>
    <description>The SPECT-based tumor-to-background ratio will be calculated as follows: the value of 99mTc-HE3-G3 uptake coinciding with tumor lesions (counts) will be divided by the value of 99mTc-HE3-G3 uptake coinciding with the regions without pathological findings (counts)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety attributable to 99mTc-HE3-G3 injections (physical findings)</measure>
    <time_frame>24 hours</time_frame>
    <description>The safety attributable to 99mTc-HE3-G3 injections will be evaluated based on the assessments of physical examination, vital signs, and ECG (% of cases with abnormal findings relative to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety attributable to 99mTc-HE3-G3 injections (laboratory tests)</measure>
    <time_frame>24 hours</time_frame>
    <description>The safety attributable to 99mTc-HE3-G3 injections will be evaluated based on the blood and urine laboratory tests (% of cases with abnormal findings relative to baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety attributable to 99mTc-HE3-G3 injections (incidence and severity of adverse events)</measure>
    <time_frame>24 hours</time_frame>
    <description>The safety attributable to 99mTc-HE3-G3 injections will be evaluated based on the rate of adverse events (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety attributable to 99mTc-HE3-G3 injections (concomitant medication)</measure>
    <time_frame>24 hours</time_frame>
    <description>The safety attributable to 99mTc-HE3-G3 injections will be evaluated based on the rate of administration of concomitant medication (%)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Primary Breast Cancer</condition>
  <arm_group>
    <arm_group_label>The tested injected doses of 99mTc-HE3-G3 1000 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.&#xD;
Subjects withdrawn from the study for any reason will be replaced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The tested injected doses of 99mTc-HE3-G3 2000 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.&#xD;
Subjects withdrawn from the study for any reason will be replaced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The tested injected doses of 99mTc-HE3-G3 3000 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.&#xD;
Subjects withdrawn from the study for any reason will be replaced.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPECT</intervention_name>
    <description>One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.</description>
    <arm_group_label>The tested injected doses of 99mTc-HE3-G3 1000 μg</arm_group_label>
    <arm_group_label>The tested injected doses of 99mTc-HE3-G3 2000 μg</arm_group_label>
    <arm_group_label>The tested injected doses of 99mTc-HE3-G3 3000 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is &gt; 18 years of age&#xD;
&#xD;
          2. Diagnosis of primary breast cancer with possible lymph node metastases&#xD;
&#xD;
          3. Availability of results from HER2 status previously determined on material from the&#xD;
             primary tumor, either&#xD;
&#xD;
               1. HER2-positive, defined as a immunohistochemical test score of 3+ or FISH positive&#xD;
                  or&#xD;
&#xD;
               2. HER2-negative, defined as a immunohistochemical test score of 0 or 1+; or else if&#xD;
                  2+ then FISH negative&#xD;
&#xD;
          4. Volumetrically quantifiable tumour lesions on CT or MRI, with at least one lesion &gt;&#xD;
             1.0 cm in greatest diameter outside of the liver and kidneys&#xD;
&#xD;
          5. Hematological, liver and renal function test results within the following limits:&#xD;
&#xD;
               -  White blood cell count: &gt; 2.0 x 10^9/L&#xD;
&#xD;
               -  Haemoglobin: &gt; 80 g/L&#xD;
&#xD;
               -  Platelets: &gt; 50.0 x 10^9/L&#xD;
&#xD;
               -  Bilirubin =&lt; 2.0 times Upper Limit of Normal&#xD;
&#xD;
               -  Serum creatinine: Within Normal Limits&#xD;
&#xD;
          6. A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at&#xD;
             screening for all patients of childbearing potential. Sexually active women of&#xD;
             childbearing potential participating in the study must use a medically acceptable form&#xD;
             of contraception for at least 30 days after study termination&#xD;
&#xD;
          7. Subject is capable to undergo the diagnostic investigations to be performed in the&#xD;
             study&#xD;
&#xD;
          8. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Second, non-breast malignancy&#xD;
&#xD;
          2. Active current autoimmune disease or history of autoimmune disease&#xD;
&#xD;
          3. Active infection or history of severe infection within the previous 3 months (if&#xD;
             clinically relevant at screening)&#xD;
&#xD;
          4. Known HIV positive or chronically active hepatitis B or C&#xD;
&#xD;
          5. Administration of other investigational medicinal product within 30 days of screening&#xD;
&#xD;
          6. Ongoing toxicity &gt; grade 2 from previous standard or investigational therapies,&#xD;
             according to US National Cancer Institute's&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir I Chernov</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tomsk NRMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TomskNRMC</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>99mTc-HE3-G3</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>HER2 expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

